{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:51:19Z","timestamp":1787781079719,"version":"build-2784847793"},"update-to":[{"DOI":"10.1371\/journal.pntd.0010616","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000}}],"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2015-02499; 2020-01365"],"award-info":[{"award-number":["2015-02499; 2020-01365"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r\u00a0Strategisk Forskning","doi-asserted-by":"publisher","award":["SB12-0003"],"award-info":[{"award-number":["SB12-0003"]}],"id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region Stockholm","award":["CIMED 2020-2022"],"award-info":[{"award-number":["CIMED 2020-2022"]}]},{"name":"Region Stockholm","award":["CIMED 2020-2022"],"award-info":[{"award-number":["CIMED 2020-2022"]}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["KID"],"award-info":[{"award-number":["KID"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Flavivirus infections pose a significant global health burden underscoring the need for the development of safe and effective vaccination strategies. Available flavivirus vaccines are from time to time concomitantly delivered to individuals. Co-administration of different vaccines saves time and visits to health care units and vaccine clinics. It serves to provide protection against multiple pathogens in a shorter time-span; e.g., for individuals travelling to different endemic areas. However, safety and immunogenicity-related responses have not been appropriately evaluated upon concomitant delivery of these vaccines. Therefore, we performed an open label, non-randomized clinical trial studying the safety and immunogenicity following concomitant delivery of the yellow fever virus (YFV) vaccine with tick-borne encephalitis virus (TBEV) and Japanese encephalitis virus (JE) virus vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>Following screening, healthy study participants were enrolled into different cohorts receiving either TBEV and YFV vaccines, JEV and YFV vaccines, or in control groups receiving only the TBEV, JEV, or YFV vaccine. Concomitant delivery was given in the same or different upper arms for comparison in the co-vaccination cohorts. Adverse effects were recorded throughout the study period and blood samples were taken before and at multiple time-points following vaccination to evaluate immunological responses to the vaccines. Adverse events were predominantly mild in the study groups. Four serious adverse events (SAE) were reported, none of them deemed related to vaccination. The development of neutralizing antibodies (nAbs) against TBEV, JEV, or YFV was not affected by the concomitant vaccination strategy. Concomitant vaccination in the same or different upper arms did not significantly affect safety or immunogenicity-related outcomes. Exploratory studies on immunological effects were additionally performed and included studies of lymphocyte activation, correlates associated with germinal center activation, and plasmablast expansion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Inactivated TBEV or JEV vaccines can be co-administered with the live attenuated YFV vaccine without an increased risk of adverse events and without reduced development of nAbs to the respective viruses. The vaccines can be delivered in the same upper arm without negative outcome. In a broader perspective, the results add valuable information for simultaneous administration of live and inactivated flavivirus vaccines in general.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Eudra\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=&amp;country=se&amp;dateFrom=2012-01-01&amp;page=21\" xlink:type=\"simple\">CT 2017-002137-32<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0010616","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T13:54:06Z","timestamp":1675950846000},"page":"e0010616","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial"],"prefix":"10.1371","volume":"17","author":[{"given":"John Tyler","family":"Sandberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"L\u00f6fling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Varnait\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Emg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Al-Tawil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lindquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gredmark-Russ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Klingstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0908-7387","authenticated-orcid":true,"given":"Hans-Gustaf","family":"Ljunggren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"pntd.0010616.ref001","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s13365-014-0285-z","article-title":"Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus","volume":"20","author":"CA Daep","year":"2014","journal-title":"J Neurovirol"},{"key":"pntd.0010616.ref002","first-page":"383","article-title":"Netter\u2019s Infectious Diseases.","author":"MD Gershman","year":"2012","journal-title":"Sect Vii Infect Assoc Int Travel Outdoor Activities"},{"key":"pntd.0010616.ref003","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1086\/515195","article-title":"Tick-Borne Encephalitis.","volume":"28","author":"U Dumpis","year":"1999","journal-title":"Clin Infect Dis"},{"key":"pntd.0010616.ref004","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0264-410X(02)00811-3","article-title":"Tick-borne encephalitis\u2014pathogenesis, clinical course and long-term follow-up","volume":"21","author":"M Haglund","year":"2003","journal-title":"Vaccine"},{"key":"pntd.0010616.ref005","unstructured":"Yellow fever. 7 May 2019 [cited 2 Feb 2022]. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/yellow-fever"},{"key":"pntd.0010616.ref006","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/microorganisms9040796","article-title":"Comparison of Clinical, Laboratory and Immune Characteristics of the Monophasic and Biphasic Course of Tick-Borne Encephalitis.","volume":"9","author":"P Bogovi\u010d","year":"2021","journal-title":"Microorg"},{"key":"pntd.0010616.ref007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jcv.2011.06.001","article-title":"A comparison of clinical features of Japanese encephalitis virus infection in the adult and pediatric age group with Acute Encephalitis Syndrome.","volume":"52","author":"J Borah","year":"2011","journal-title":"J Clin Virol"},{"key":"pntd.0010616.ref008","unstructured":"Tick-borne encephalitis. 2 Oct 2017 [cited 2 Feb 2022]. Available: https:\/\/www.who.int\/health-topics\/tick-borne-encephalitis#tab=tab_1"},{"key":"pntd.0010616.ref009","unstructured":"Japanese encephalitis. 9 May 2019 [cited 2 Feb 2022]. Available: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/japanese-encephalitis"},{"key":"pntd.0010616.ref010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2019.01.004","article-title":"Tick-borne encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention, and treatment","volume":"62","author":"N Riccardi","year":"2019","journal-title":"Eur J Intern Med"},{"key":"pntd.0010616.ref011","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3988\/jcn.2021.17.3.428","article-title":"Clinical Outcomes of Japanese Encephalitis after Combination Treatment of Immunoglobulin, Ribavirin, and Interferon-\u03b12b.","volume":"17","author":"H Son","year":"2021","journal-title":"J Clin Neurol."},{"key":"pntd.0010616.ref012","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.tim.2018.05.012","article-title":"Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe","volume":"26","author":"F Douam","year":"2018","journal-title":"Trends Microbiol"},{"key":"pntd.0010616.ref013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.virol.2019.11.015","article-title":"Novel anti-flavivirus drugs targeting the nucleolar distribution of core protein","volume":"541","author":"M Tokunaga","year":"2020","journal-title":"Virology"},{"key":"pntd.0010616.ref014","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/cmdc.202000464","article-title":"Broad-Spectrum Flavivirus Inhibitors: a Medicinal Chemistry Point of View","volume":"15","author":"T Felicetti","year":"2020","journal-title":"Chemmedchem"},{"key":"pntd.0010616.ref015","unstructured":"FSME-IMMUN Vuxen\u2014FASS V\u00e5rdpersonal. [cited 16 Nov 2021]. Available: https:\/\/www.fass.se\/LIF\/product?userType=0&nplId=20040206000026&docType=7&scrollPosition=255"},{"key":"pntd.0010616.ref016","unstructured":"IXIARO\u2014FASS V\u00e5rdpersonal. [cited 16 Nov 2021]. Available: https:\/\/www.fass.se\/LIF\/product?userType=0&nplId=20080207000014"},{"key":"pntd.0010616.ref017","unstructured":"Stamaril\u2014FASS V\u00e5rdpersonal. [cited 16 Nov 2021]. Available: https:\/\/www.fass.se\/LIF\/product?userType=0&nplId=19940408000036"},{"key":"pntd.0010616.ref018","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Review article: Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years","volume":"89","author":"E Gotuzzo","year":"2013","journal-title":"Am J Tropical Medicine Hyg"},{"key":"pntd.0010616.ref019","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of Protection Induced by Vaccination\u25bf","volume":"17","author":"SA Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"pntd.0010616.ref020","volume-title":"Plotkin\u2019s Vaccines.","author":"SA Plotkin","year":"2017","edition":"7"},{"key":"pntd.0010616.ref021","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(08)60800-4","article-title":"Tick-borne encephalitis.","volume":"371","author":"L Lindquist","year":"2008","journal-title":"Lancet"},{"key":"pntd.0010616.ref022","article-title":"Immunization Strategies for Healthcare Practices and Providers | CDC.","author":"A Bj\u00f6rk","year":"2021","journal-title":"In: Immunization Strategies for Healthcare Practices and Providers [Internet]."},{"key":"pntd.0010616.ref023","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0264-410X(94)90267-4","article-title":"Combined vaccination against yellow fever and typhoid fever: a comparative trial","volume":"12","author":"F Ambrosch","year":"1994","journal-title":"Vaccine"},{"key":"pntd.0010616.ref024","doi-asserted-by":"crossref","first-page":"906","DOI":"10.4161\/hv.6.11.12854","article-title":"Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine.","volume":"6","author":"PE Nasveld","year":"2010","journal-title":"Hum Vaccines."},{"key":"pntd.0010616.ref025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tmaid.2015.05.008","article-title":"Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine","volume":"13","author":"T Jelinek","year":"2015","journal-title":"Travel Med Infect Di"},{"key":"pntd.0010616.ref026","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/INF.0000000000001250","article-title":"Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12\u201313 Months of Age in Colombia and Peru.","volume":"35","author":"P L\u00f3pez","year":"2016","journal-title":"Pediatric Infect Dis J."},{"key":"pntd.0010616.ref027","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1016\/j.vaccine.2011.05.019","article-title":"Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella","volume":"29","author":"JRN Silva","year":"2011","journal-title":"Vaccine"},{"key":"pntd.0010616.ref028","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0264-410X(97)00304-6","article-title":"Passive immunization reduces immunity that results from simultaneous active immunization against tick-borne encephalitis virus in a mouse model","volume":"16","author":"TR Kreil","year":"1998","journal-title":"Vaccine"},{"key":"pntd.0010616.ref029","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1016\/j.vaccine.2009.05.034","article-title":"Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study","volume":"27","author":"A Kaltenb\u00f6ck","year":"2009","journal-title":"Vaccine"},{"key":"pntd.0010616.ref030","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/S0264-410X(03)00028-8","article-title":"Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice","volume":"21","author":"E Konishi","year":"2003","journal-title":"Vaccine"},{"key":"pntd.0010616.ref031","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijid.2004.03.006","article-title":"Vaccines administered simultaneously: directions for new combination vaccines based on an historical review of the literature","volume":"8","author":"MA Fletcher","year":"2004","journal-title":"Int J Infect Dis"},{"key":"pntd.0010616.ref032","first-page":"964","article-title":"Simultaneous Immunization with Multiple Diverse Immunogens Alters Development of Antigen-Specific Antibody-Mediated Immunity.","volume":"9","author":"KA Pilewski","year":"2021","journal-title":"Nato Adv Sci Inst Se"},{"key":"pntd.0010616.ref033","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0264-410X(95)80020-E","article-title":"Simultaneous injection of plasma-derived or recombinant hepatitis B vaccines with yellow fever and killed polio vaccines","volume":"13","author":"P Coursaget","year":"1995","journal-title":"Vaccine"},{"key":"pntd.0010616.ref034","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/infdis\/126.4.362","article-title":"Effect of interval between inoculation of live smallpox and yellow-fever vaccines on antigenicity in man","volume":"126","author":"NM Tauraso","year":"1972","journal-title":"J Infect Dis"},{"key":"pntd.0010616.ref035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(73)91882-5","article-title":"SIMULTANEOUS VACCINATION AGAINST CHOLERA AND YELLOW FEVER.","volume":"301","author":"O Felsenfeld","year":"1973","journal-title":"Lancet"},{"key":"pntd.0010616.ref036","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/21645515.2017.1389363","article-title":"Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination.","volume":"14","author":"P Kaaijk","year":"2017","journal-title":"Hum Vacc Immunother"},{"key":"pntd.0010616.ref037","first-page":"524","article-title":"Climate Warming and Tick-borne Encephalitis, Slovakia\u2014Volume 16, Number 3\u2014March 2010\u2014Emerging Infectious Diseases journal\u2014CDC","volume":"16","author":"M Lukan","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"pntd.0010616.ref038","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","article-title":"The continued threat of emerging flaviviruses.","volume":"5","author":"TC Pierson","year":"2020","journal-title":"Nat Microbiol"},{"key":"pntd.0010616.ref039","unstructured":"ICH GCP\u2014ICH harmonised guideline integrated addendum to ICH E6(R1): Guideline for Good Clinical Practice ICH E6(R2) ICH Consensus Guideline\u2014ICH GCP. [cited 31 Jan 2022]. Available: https:\/\/ichgcp.net\/sv"},{"key":"pntd.0010616.ref040","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","article-title":"Human Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines","volume":"28","author":"JD Miller","year":"2008","journal-title":"Immunity"},{"key":"pntd.0010616.ref041","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0166-0934(98)00041-X","article-title":"A rapid fluorescent focus inhibition test for detection of neutralizing antibodies to tick-borne encephalitis virus","volume":"73","author":"S Vene","year":"1998","journal-title":"J Virol Methods"},{"key":"pntd.0010616.ref042","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.4049\/jimmunol.1401811","article-title":"The Human NK Cell Response to Yellow Fever Virus 17D Is Primarily Governed by NK Cell Differentiation Independently of NK Cell Education","volume":"195","author":"N Marquardt","year":"2015","journal-title":"J Immunol"},{"key":"pntd.0010616.ref043","doi-asserted-by":"crossref","first-page":"ji2001381","DOI":"10.4049\/jimmunol.2001381","article-title":"Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination","volume":"207","author":"JT Sandberg","year":"2021","journal-title":"J Immunol"},{"key":"pntd.0010616.ref044","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1016\/j.vaccine.2006.03.061","article-title":"Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: Results of two large phase 3 clinical studies","volume":"24","author":"A Loew-Baselli","year":"2006","journal-title":"Vaccine"},{"key":"pntd.0010616.ref045","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1016\/j.vaccine.2011.08.117","article-title":"Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO.","volume":"29","author":"E Schuller","year":"2011","journal-title":"Vaccine"},{"key":"pntd.0010616.ref046","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/14760584.2013.836320","article-title":"Safety profile of the yellow fever vaccine Stamaril: a 17-year review.","volume":"12","author":"P Cottin","year":"2014","journal-title":"Expert Rev Vaccines."},{"key":"pntd.0010616.ref047","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/joim.12638","article-title":"Prospects for induction of CD8 T cell-mediated immunity to Zika virus infection by yellow fever virus vaccination","volume":"282","author":"K Blom","year":"2017","journal-title":"J Intern Med"},{"key":"pntd.0010616.ref048","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/erv.11.180","article-title":"Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.","volume":"11","author":"M Lobigs","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"pntd.0010616.ref049","doi-asserted-by":"crossref","first-page":"eaar4297","DOI":"10.1126\/sciadv.aar4297","article-title":"Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells.","volume":"4","author":"WAA Saron","year":"2018","journal-title":"Sci Adv."},{"key":"pntd.0010616.ref050","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1016\/j.vaccine.2005.04.036","article-title":"The suitability of yellow fever and Japanese encephalitis vaccines for immunization against West Nile virus","volume":"23","author":"G Yamshchikov","year":"2005","journal-title":"Vaccine"},{"key":"pntd.0010616.ref051","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41541-019-0133-5","article-title":"Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination","volume":"4","author":"V Bradt","year":"2019","journal-title":"Npj Vaccines"},{"key":"pntd.0010616.ref052","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/(SICI)1096-9071(199601)48:1<102::AID-JMV16>3.0.CO;2-I","article-title":"Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis","volume":"48","author":"H Holzmann","year":"1996","journal-title":"J Med Virol"},{"key":"pntd.0010616.ref053","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.4049\/jimmunol.1202234","article-title":"Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response","volume":"190","author":"K Blom","year":"2013","journal-title":"J Immunol"},{"key":"pntd.0010616.ref054","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"SL Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"pntd.0010616.ref055","doi-asserted-by":"crossref","first-page":"e0149871","DOI":"10.1371\/journal.pone.0149871","article-title":"A single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination","volume":"11","author":"RW Wieten","year":"2016","journal-title":"Plos One."},{"key":"pntd.0010616.ref056","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/v13010096","article-title":"Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-\u03b3 and CLEC5A.","volume":"13","author":"T Azamor","year":"2021","journal-title":"Viruses"},{"key":"pntd.0010616.ref057","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2249.2006.03317.x","article-title":"Activation\/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?","volume":"148","author":"M\u00c2 Martins","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"pntd.0010616.ref058","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3389\/fimmu.2018.02309","article-title":"Comparative Analysis of B-Cell Receptor Repertoires Induced by Live Yellow Fever Vaccine in Young and Middle-Age Donors.","volume":"9","author":"AN Davydov","year":"2018","journal-title":"Front Immunol"},{"key":"pntd.0010616.ref059","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3389\/fimmu.2019.01211","article-title":"Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.","volume":"10","author":"IA da Costa-Rocha","year":"2019","journal-title":"Front Immunol."},{"key":"pntd.0010616.ref060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cti2.1129","article-title":"Dynamic changes in circulating T follicular helper cell composition predict neutralising antibody responses after yellow fever vaccination","volume":"9","author":"JE Huber","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"pntd.0010616.ref061","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1128\/JVI.03203-15","article-title":"B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.","volume":"90","author":"L Priyamvada","year":"2016","journal-title":"J Virol"},{"key":"pntd.0010616.ref062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2021.03.013","article-title":"Positive selection of IgG+ over IgM+ B cells in the germinal center reaction","volume":"54","author":"C Sundling","year":"2021","journal-title":"Immunity"},{"key":"pntd.0010616.ref063","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1016\/j.vaccine.2016.04.097","article-title":"Evaluation of potentially achievable vaccination coverage with simultaneous administration of vaccines among children in the United States","volume":"34","author":"Z Zhao","year":"2016","journal-title":"Vaccine"},{"key":"pntd.0010616.ref064","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.inf.0000114902.84651.02","article-title":"Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine&colon; safety, tolerability and immunogenicity.","volume":"23","author":"TM HESLEY","year":"2004","journal-title":"Pediatric Infect Dis J."},{"key":"pntd.0010616.ref065","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1708-8305.1998.tb00483.x","article-title":"Concomitant Vaccination against Hepatitis A and Typhoid Fever.","volume":"5","author":"C Hoecke","year":"1998","journal-title":"J Travel Med"},{"key":"pntd.0010616.ref066","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/pds.4399","article-title":"Methods for addressing \u201cinnocent bystanders\u201d when evaluating safety of concomitant vaccines.","volume":"27","author":"SV Wang","year":"2018","journal-title":"Pharmacoepidem Dr S"},{"key":"pntd.0010616.ref067","first-page":"jiab611","article-title":"Phase 1\/2 Randomized Study of the Immunogenicity, Safety and Tolerability of an RSV Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine","author":"AR Falsey","year":"2021","journal-title":"J Infect Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0010616","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T13:40:26Z","timestamp":1677073226000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010616"}},"subtitle":[],"editor":[{"given":"Wei-Kung","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0010616","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.07.05.22277040","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}